211 related articles for article (PubMed ID: 36595067)
41. The role of PET imaging in lymphoma.
Burton C; Ell P; Linch D
Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
[TBL] [Abstract][Full Text] [Related]
42. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
43. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
[TBL] [Abstract][Full Text] [Related]
44. PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Phillips EH; Iype R; Wirth A
Br J Radiol; 2021 Nov; 94(1127):20210576. PubMed ID: 34520242
[TBL] [Abstract][Full Text] [Related]
45. Gallium-67 scintigraphy in the management: Hodgkin's disease and non-Hodgkin's lymphoma.
Rehm PK
Cancer Biother Radiopharm; 1999 Aug; 14(4):251-62. PubMed ID: 10850311
[TBL] [Abstract][Full Text] [Related]
46. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
47. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
48. Application of DWIBS in malignant lymphoma: correlation between ADC values and Ki-67 index.
Sun M; Cheng J; Zhang Y; Bai J; Wang F; Meng Y; Li Z
Eur Radiol; 2018 Apr; 28(4):1701-1708. PubMed ID: 29143105
[TBL] [Abstract][Full Text] [Related]
49. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
50. Response assessment in lymphoma.
Hampson FA; Shaw AS
Clin Radiol; 2008 Feb; 63(2):125-35. PubMed ID: 18194687
[TBL] [Abstract][Full Text] [Related]
51.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
52. Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients.
Amini RM; Enblad G; Sundström C; Glimelius B
Int J Cancer; 1997 May; 71(4):510-6. PubMed ID: 9178801
[TBL] [Abstract][Full Text] [Related]
53. Sonography in the diagnosis and therapy monitoring of lymphomas.
Wojnar J; Kalina Z; Stella-Hołowiecka B; Krawczyk-Kuliś M; Wróbel R; Hołowiecki J
Neoplasma; 1992; 39(4):261-6. PubMed ID: 1436240
[TBL] [Abstract][Full Text] [Related]
54. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma.
Mink SA; Armitage JO
Oncologist; 2001; 6(3):247-56. PubMed ID: 11423671
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
Spaepen K; Stroobants S; Verhoef G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831
[TBL] [Abstract][Full Text] [Related]
56. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
57. Lymphographic patterns of the subtypes of malignant lymphoma, including Hodgkin's disease.
Schellinger D; Miller WE; Harrison EG; Kiely JM
Radiology; 1974 May; 111(2):257-66. PubMed ID: 4594536
[No Abstract] [Full Text] [Related]
58. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
59. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
Maisey NR; Hill ME; Webb A; Cunningham D; Flux GD; Padhani A; Ott RJ; Norman A; Bishop L
Eur J Cancer; 2000 Jan; 36(2):200-6. PubMed ID: 10741278
[TBL] [Abstract][Full Text] [Related]
60. [Malignant lymphoma: a study of an outpatient cohort].
Burla M; Egli F; Rhyner K
Schweiz Rundsch Med Prax; 1990 Jan; 79(5):101-10. PubMed ID: 2305142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
